Prevalence and Characteristics of Hyperferritinemia in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis - PubMed
5 hours ago
- #Hyperferritinemia
- #Meta-Analysis
- #MASLD
- Hyperferritinemia (HF) is present in approximately 26.36% of patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- Prevalence of HF in MASLD is highest in Asia (30.89%) and lowest in North America (20.22%).
- HF is more common in biopsy-proven MASLD (32.61%) and similarly prevalent (24.87%) when using the consensus definition of HF.
- MASLD-HF patients are more likely to be male and exhibit higher levels of triglycerides, HbA1c, insulin resistance, and liver enzymes.
- HF is associated with advanced liver disease features, including steatohepatitis, significant fibrosis, and a higher incidence of liver-related events (HR 2.02).
- SF (serum ferritin) is highlighted as a simple, accessible biomarker for identifying higher-risk MASLD phenotypes.